The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 3, 2000, Pages 268-272

  Kucharewicz, Iwona ^a   Chabielska, Ewa ^a   Pawlak, Dariusz ^a   Matys, Tomasz ^a   Rólkowski, Roland ^b   Buczko, Wlodzimierz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Centre of Oncology   (Poland)

Author keywords

Angiotensin (1.7); Losartan; Venous thrombosis

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); ANTIHYPERTENSIVE AGENT; COLLAGEN; FIBRINOLYTIC AGENT; LOSARTAN; PEPTIDE FRAGMENT;

ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG EFFECT; HEMOSTASIS; MALE; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOCYTE ADHESIVENESS; VEIN THROMBOSIS; WISTAR RAT;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COLLAGEN; FIBRINOLYTIC AGENTS; HEMOSTASIS; LOSARTAN; MALE; PEPTIDE FRAGMENTS; PLATELET ADHESIVENESS; RATS; RATS, INBRED SHR; RATS, WISTAR; VENOUS THROMBOSIS;

EID: 0034285712     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.041     Document Type: Article

References (25)

1. Cachofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V. Nitric oxide and prostacyclin in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995; 26: 236-43.
2. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol 1999; 10: S30-S39.
3. McIntyre M, Caffe SA, Michalak RA, Reid JL. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Ther 1997; 74: 181-94.
4. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
5. Pitt B, Poole-Wilson PA, Segale R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-87.
6. Iyer SN, Chappell MC, Averill DB, Diz DI, Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998; 31: 669-705.
7. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997; 30: 535-41.
8. Chabielska E, Pawlak R, Golatowski J, Rólkowski R, Buczko W. Losartan inhibits the experimental venous thrombosis in spontaneously hypertensive rats. Thromb Res 1998; 90: 271-8.
9. Chabielska E, Pawlak R, Wollny T, Rólkowski R, Buczko W. Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. J Physiol Pharmacol 1999; 50: 99-109.
10. Zatz R. A low-cost tail-cuff method for the estimation of mean arterial pressure in conscious rats. Lab Anim Sci 1990; 42: 198-201.
11. Reyers I, DeGaetano G, Donati MB. Venostasis-induced thrombosis in rat is not influenced by circulating platelet or leukocyte number. Agents Actions 1989; 28: 137-40.
12. Radomski MW, Palmer MJR, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-89.
13. Pawlak R, Chabielska E, Golatowski J, Azzadin A, Buczko W Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 1998; 79: 1208-12.
14. Abramczyk P, Lisiecka A, Papierski K, Ziecina R, Przybylski J.Arterial hypertension due to occlusion of the adrenal vein in the rat is strain-dependent. J Hypertens 1998; 16: 1249-51.
15. Ploth DW. Angiotensin-dependent renal mechanisms in two-kidney, one-clip renal vascular hypertension. Am J Physiol 1983; 245: F131-F141.
16. Moriguchi A, Brosnihan KD, Kumagai H, Ganten D, Ferrario CM. Mechanism of hypertension in transgenic rats expressing mouse Ren-2 gene. Am J Physiol 1994; 266: R1273-R1279.
17. 4 receptor system. Am J Physiol 1999; 277: F75-F83.
18. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by hexapeptide angiotensin IV. J Clin Invest 1995; 96: 2515-20.
19. Provost P, Lam JYT, Lacoste L, Merhi Y, Waters D. Endothelium - derived nitric oxide attenuates neutrophil adhesion to endothelium under arterial flow conditions. Arterioscler Thromb 1994; 14: 331-5.
20. 1-receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens 1993; 11: 5230-31.
21. Moore TJ, Williams GH.Angiotensin II receptors on human platelets. Circ Res 1982; 51: 314-20.
22. Campbell DJ, Menard J, Azizi M, Gonzales MF. Synergistic interaction between angiotensin converting enzyme inhibition and angiotensin II antagonism in spontaneously hypertensive rats. J Hypertens 1997; 15(suppl): S63.
23. Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998; 32: 198-205.
24. 2 (TP) receptors. Prostaglandins 1992; 44: 89-99.
25. Guera-Cuesta JI, Monton M, Rodriquez Feo JA et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447-52.